Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

GH Research PLC

GHRS
Current price
8.97 USD -0.45 USD (-4.78%)
Last closed 9.24 USD
ISIN IE000GID8VI0
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 447 961 920 USD
Yield for 12 month +13.98 %
1Y
3Y
5Y
10Y
15Y
GHRS
21.11.2021 - 28.11.2021

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Address: Joshua Dawson House, Dublin, Ireland, D02 RY95

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

32 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+80 000 USD

Current Year

-315 000 USD

Last Year

-47 000 USD

Current Quarter

-78 000 USD

Last Quarter

Key Figures GHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -45 526 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -12.74 %
PEG Ratio
Return On Equity TTM -16.2 %
Wall Street Target Price 32 USD
Revenue TTM
Book Value 3.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -0.67 USD
Diluted Eps TTM -0.67 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics GHRS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation GHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -11.9745
Price Book MRQ 2.2547

Financials GHRS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GHRS

For 52 weeks

5.05 USD 14.99 USD
50 Day MA 7.76 USD
Shares Short Prior Month 1 601 025
200 Day MA 10.09 USD
Short Ratio 29.92
Shares Short 1 779 944
Short Percent 12.03 %